Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.39 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25690742 | 0.84 | KMT2A (0.56) | KMT2AKDM4EMAPK1HPGDL3MBTL1 | |
| SCHEMBL6194088 | 0.80 | KMT2A (0.45) | KMT2AKDM4EMAPK1ALDH1A1LMNA | |
| SCHEMBL7713608 | 0.77 | APP (0.44) | KDM4EMAPK1ALDH1A1LMNAHPGD | |
| SCHEMBL22596691 | 0.75 | HPGD (0.43) | KMT2AKDM4EMAPK1HPGDPTGS2 | |
| SCHEMBL18831734 | 0.74 | CA1 (0.41) | KMT2AKDM4EMAPK1ALDH1A1LMNA | |
| SCHEMBL9385104 | 0.74 | L3MBTL1 (0.53) | KMT2AKDM4EALDH1A1NR3C1TP53 | |
| SCHEMBL22589746 | 0.74 | KMT2A (0.40) | KMT2AKDM4EMAPK1HPGDMEN1 | |
| SCHEMBL25688214 | 0.72 | GAA (0.51) | KMT2AALDH1A1LMNAHPGDL3MBTL1 | |
| SCHEMBL9957659 | 0.71 | KMT2A (0.44) | KMT2AKDM4EMAPK1ALDH1A1LMNA | |
| SCHEMBL12871703 | 0.70 | GAA (0.53) | KMT2AKDM4EMAPK1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373267-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM CA LTD (CA) | 2005-02-02 | — | — | EP | disclosed |
| US-6716836-B2 | BENZOTHIAZOLE OR BENZOTHIAZINE DERIVATIVES OF DIPYRIDO(3,2B:2',3'-E)(1,4-DIAZEPIN-6-ONE | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-04-06 | — | — | US | disclosed |
| US-20030069226-A1 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069226-A1 | Non-nucleoside reverse transcriptase inhibitors | RCOR1, CBR1, SUB1 | KMT2A 1253/4885KDM4E 429/4885MAPK1 1758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.